UNCY Q3 EPS Forecast Increased by Brookline Capital Markets

Posted by George Bondi on Jul 3rd, 2026

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Analysts at Brookline Capital Markets increased their Q3 2026 earnings estimates for shares of Unicycive Therapeutics in a research report issued to clients and investors on Tuesday, June 30th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn ($0.30) per share for the quarter, up from their previous forecast of ($0.34). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $3.35 EPS, FY2028 earnings at $3.14 EPS and FY2029 earnings at $4.09 EPS.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08).

A number of other research firms have also recently commented on UNCY. B. Riley Financial restated a “buy” rating and issued a $22.00 price objective on shares of Unicycive Therapeutics in a research report on Tuesday. Noble Financial cut their price target on shares of Unicycive Therapeutics from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Wednesday. HC Wainwright reduced their price objective on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings raised shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. Finally, Benchmark dropped their target price on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a research report on Wednesday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.40.

Check Out Our Latest Report on Unicycive Therapeutics

Unicycive Therapeutics Trading Up 8.5%

Shares of UNCY stock opened at $5.73 on Friday. The company has a market capitalization of $156.94 million, a P/E ratio of -2.59 and a beta of 1.79. The business’s 50 day moving average is $7.43 and its two-hundred day moving average is $6.81. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $8.74.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UNCY. Lazard Asset Management LLC purchased a new position in Unicycive Therapeutics during the 2nd quarter valued at about $55,000. JPMorgan Chase & Co. grew its stake in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Unicycive Therapeutics during the 1st quarter worth approximately $161,000. Citadel Advisors LLC purchased a new stake in Unicycive Therapeutics in the 3rd quarter worth approximately $182,000. Finally, Bank of America Corp DE boosted its holdings in Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares during the period. Institutional investors own 40.42% of the company’s stock.

More Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

Negative Sentiment: Investors are reacting to reports that Unicycive received a second FDA Complete Response Letter, with articles saying the agency cited third-party manufacturing deficiencies. That keeps regulatory uncertainty high and appears to be the main pressure on the stock. Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
Negative Sentiment: Multiple law firms, including Kirby McInerney, Bragar Eagel & Squire, and Block & Leviton, announced securities-fraud investigations tied to the FDA update, which can add overhang and worsen investor sentiment. UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT
Negative Sentiment: HC Wainwright and Noble Financial sharply reduced near-term earnings estimates for 2026 and 2027, signaling more caution around the company’s path to profitability even though both firms kept bullish ratings. MarketBeat UNCY analyst updates
Neutral Sentiment: Despite the estimate cuts, analysts such as HC Wainwright and Noble Financial still have Buy/Outperform ratings and price targets well above the current share price, which may help limit downside if investors focus on longer-term commercialization potential. MarketBeat UNCY analyst updates

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.